Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 51

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 51
---
 comprehensive loss, net of tax, for the nine months ended September 30, 2024:(in millions)Foreign currency translation adjustmentsNet investmenthedging activitiesPension and post-employment benefitsCash flow hedging activitiesTotalBalance as of December 31, 2023$(1,106)$65 $(1,488)$224 $(2,305)Other comprehensive income (loss) before reclassifications21 31 (4)20 68 Net losses (gains) reclassified from accumulated other comprehensive loss— (70)19 (46)(97)Net current-period other comprehensive income (loss)21 (39)15 (26)(29)Balance as of September 30, 2024$(1,085)$26 $(1,473)$198 $(2,334)The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions) (brackets denote gains)2025202420252024Net investment hedging activitiesGains on derivative amount excluded from effectiveness testing(a)$(37)$(32)$(108)$(90)Tax expense8 7 23 20 Total reclassifications, net of tax$(29)$(25)$(85)$(70)Pension and post-employment benefitsAmortization of actuarial losses and other(b)$2 $8 $4 $25 Tax benefit(1)(2)(2)(6)Total reclassifications, net of tax$1 $6 $2 $19 Cash flow hedging activitiesGains on foreign currency forward exchange contracts(c)$(41)$(19)$(69)$(41)Other(a)(5)(6)(15)(18)Tax expense8 5 16 13 Total reclassifications, net of tax$(38)$(20)$(68)$(46)(a) Amounts are included in interest expense, net (see Note 8).(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).(c) Amounts are included in cost of products sold (see Note 8).

Note 11 Income Taxes The effective tax rate was 74% for the three months and 39% for the nine months ended September 30, 202